Novo’s younger sibling has growing pains
Novo Nordisk’s lesser-known haemophilia division is moving into the limelight. There is a much bigger patient population waiting that we have not even begun to focus on, the VP in charge of the division says. But Novo’s younger sibling will be facing some of the big boys in the schoolyard.
by Stefan Singh Kailay
They are gearing up for something big in Novo Nordisk’s haemophilia division. But to the general public the disease haemophilia is not normally what you would associate the Danish pharmaceutical giant with.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
